New application of ginkgolide B

A technology of ginkgolide and medicine, which is applied in the new application field of ginkgolide B, and can solve the problems of ginkgolide toxicity and unproven effects

Inactive Publication Date: 2011-04-20
PEKING UNIV
View PDF1 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0019] 7. Potential toxic effects of ginkgolide B
Animal experiments have confirmed that the application of angiotensin-converting enzyme inhibitors (angiotensin-convertingenzyme inhibitors, ACEI) or angiotensin receptor blocker (angiotensin receptor blocker, ARB) to control blood pressure may delay polycystic kidney failure, but some Clinical studies have not confirmed its effect (Tao Y, Kim J, Yin Y, et al. VEGF receptor inhibition slows the progression of polycystic kidney disease. Kidney Int, 2007, 72(11): 1358-66.)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of ginkgolide B
  • New application of ginkgolide B
  • New application of ginkgolide B

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] Example 1, Ginkgolide B inhibits the formation and growth of MDCK vesicles

[0064] 1. Ginkgolide B can inhibit the formation of vesicles, and the effect has a dose-effect relationship

[0065] 1. Vesicle formation inhibition experiment

[0066] Canine kidney cells (MDCK) were stimulated by cAMP to form vesicles when cultured in three-dimensional Matrigel, and they continued to grow. Forskolin is an activator of adenylyl cyclase, which can mediate the generation of cAMP, so forskolin can promote the formation and growth of MDCK vesicles, whose vesicle properties are similar to those of polycystic kidney vesicles, It is the best in vitro model for screening and evaluating the pharmacological activity of compounds for treating polycystic kidney disease.

[0067] MDCK cells (purchased from ATCC, USA, catalog number CCL-34) were cultured in culture media containing 10 μM forskolin (forskolin, purchased from Sigma, catalog number F6886) and concentrations of 0 M, 12.5×10 ...

Embodiment 2

[0072] Embodiment 2, the cytotoxicity of ginkgolide B, the impact on cell growth and differentiation

[0073] 1. Determine the cytotoxicity of ginkgolide B by MTT assay

[0074] The log phase MDCK cell suspension was inoculated in a 96-well culture plate, and each well contained 4×10 3 Each well was given 200 μl of MDCK cell culture medium (made from DMEM medium (purchased from U.S. Invitrogen Company, catalog number 12100-046) and F12 medium (purchased from U.S. Invitrogen Company, catalog No. 21700-075) in equal volumes. mixed), placed in 5% CO at 37°C 2 Incubate for 24 hours in the incubator. Then add the final concentration of 1 × 10 to the cell culture plate -4 M, 1×10 -5 M, 1×10 -6 M and 1×10 -7 M ginkgolide B 20μl, continue to culture for 24 hours. Remove the supernatant, add 200 μl MDCK cell culture medium and 20 μl MTT solution with a concentration of 5 mg / ml, and continue to cultivate for 3 hours. Remove the supernatant, add 150 μl dimethyl sulfoxide to each ...

Embodiment 3

[0085] Example 3. Determination of the inhibitory effect of ginkgolide B on the growth of embryonic kidney vesicles by an in vitro embryonic kidney model

[0086] On the afternoon of the first day, 6-week-old ICR mice (purchased from the Experimental Animal Center of Peking University Health Science Center) were mated in the same cage at a ratio of 1:1. It means that the female mice have been pregnant for half a day, and the mice without vaginal plugs are divided into cages first, and then re-caged in the afternoon, and then observed on the second day; the pregnant female mice continue to be fed alone for 13 days, and the embryonic kidneys are taken on the 13th day and cultured on a transwell plate.

[0087] Take the 13.5-day-old mouse embryonic kidney and under the action of 100 μm 8-Br-cAMP (purchased from Sigma, product number B-1381), multiple and progressive renal vesicles will be formed in the kidney tissue, which can be used as an evaluation An in vitro whole-organ mode...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses application of ginkgolide B to preparation of medicament for preventing and / or treating autosomal dominant polycystic kidney disease. A madin-darby canine kidney (MDCK) vesicle model is used for screening to find that the ginkgolide B inhibits formation and growth of vesicles. An experimental result shows that: the ginkgolide B has an obvious inhibiting effect on the formation and growth of MDCK vesicles and the effect of the ginkgolide B is in dose response relationship; the ginkgolide B has no cytotoxicity to MDCK cells, so that the vesicle inhibiting effect of the ginkgolide B is independent of the cytotoxicity; the ginkgolide B does not obviously induce MDCK cell apoptosis, so that the vesicle inhibiting effect of the ginkgolide B is independent of cell apoptosis promotion of the ginkgolide B; the ginkgolide B can promote the MDCK cells or vesicles to form tubular structures; and the effect is in dose response relationship; and the ginkgolide B has an inhibiting effect on the growth of the embryonic kidney vesicles. The ginkgolide B provides experimental data for development of a specific medicament for preventing and / or treating autosomal dominant polycystic kidney disease.

Description

technical field [0001] The invention relates to a new application of ginkgolide B. Background technique [0002] 1. Chemical characteristics and pharmacological effects of ginkgolide B [0003] 1. General characteristics of ginkgolide B [0004] Ginkgolides (ginkgolides) are a kind of terpenoid lactone compound extracted from Ginkgo biloba, including ginkgolides A, B, C, J, K, L and M, and ginkgolides are platelet activating factors (platelet activating factors). factor, PAF) inhibitor, wherein, ginkgolide B (ginkgolideB, GB, the chemical structural formula of ginkgolide B is as figure 1 shown) is the strongest pharmacological activity of ginkgolides (van Beek TA. Ginkgolides and bilobalide: their physical, chromatographic and spectroscopic properties. Bioorg Med Chem, 2005, 13 (17): 5001-12. Vogensen SB, Stromgaard K, Shindou H, et al. Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem, 2003, 46(4...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61P13/12
Inventor 杨宝学周虹高晋生雷天落
Owner PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap